The online version of this article (doi:10.1186/1476-5926-11-4) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
NAK made all experiments, data analysis and wrote the paper, EC had worked in cytometry analysis and results discuss, UM gave the laboratory supply and help in on the discussion of results and review the paper, NM gave the financial support and laboratory supply and CAM helped in article writing and revision of data. All Authors read and approved the final manuscript.
Liver cancer is one of the most common malignancies in the world and at the moment, there is no drug intervention effective for the treatment of liver tumours. Investigate the effect of N-acetylcysteine (NAC), which has been studied for its antitumoural properties, on the toxicity of hepatocarcinoma (HCC) cells in vitro when used with the drug interferon alpha-2A (IFN), which is used clinically to treat HCC.
NAC, IFN and NAC plus IFN reduced cell viability, as determined by MTT assay. More importantly, NAC potentiates the cytotoxic effect of IFN, with the best response achieved with 10 mM of NAC and 2.5 x 104 of IFN. These results were confirmed by Annexin/PI staining through flow cytometry and morphologic analyses. Co-treatment reduced the expression of the nuclear transcription factor kappa-B (NF-kB). In a similar way to NAC, RNAi against p65 potentiated the toxic effect of IFN, suggesting that, indeed, NAC may be enhancing the effect of IFN through inhibition of NF-kB.
Our results support the notion that NAC may be an important drug for the treatment of liver tumours as primary or adjuvant therapy. IFN has a limited clinical response, and therefore, the anti-proliferative properties of NAC in the liver should be explored further as an alternative for non-responders to IFN treatment.
Authors’ original file for figure 112946_2011_146_MOESM1_ESM.tiff
Authors’ original file for figure 212946_2011_146_MOESM2_ESM.tiff
Authors’ original file for figure 312946_2011_146_MOESM3_ESM.tiff
Authors’ original file for figure 412946_2011_146_MOESM4_ESM.tiff
Authors’ original file for figure 512946_2011_146_MOESM5_ESM.tiff
Authors’ original file for figure 612946_2011_146_MOESM6_ESM.tiff
Authors’ original file for figure 712946_2011_146_MOESM7_ESM.tiff
Authors’ original file for figure 812946_2011_146_MOESM8_ESM.tiff
Authors’ original file for figure 912946_2011_146_MOESM9_ESM.tiff
Authors’ original file for figure 1012946_2011_146_MOESM10_ESM.tiff
Pache I, Bize P, Halkic N, Montemurro M, Giostra E, Majno P, Moradpour D: [Management of hepatocellular carcinoma]. Rev Med Suisse. 2010, 6: 198-202. PubMed
El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, El-Bassiouni N: Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. APMIS. 2006, 114: 420-427. 10.1111/j.1600-0463.2006.apm_323.x. CrossRefPubMed
Zhuang P, Zhang J, Zhang W, Zhu X, Liang Y, Xu H, Xiong Y, Kong L, Wang L, Wu W, Tang Z, Qin L, Sun H: Long-term interferon-alpha treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010, 136: 1891-1900. 10.1007/s00432-010-0848-1. CrossRefPubMed
Fillmann H, Kretzmann N, San-Miguel B, Llesuy S, Marroni N, González-Gallego J, Tuñón M: Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology. 2007, 236: 217-226. 10.1016/j.tox.2007.04.012. CrossRefPubMed
Millea P: N-acetylcysteine: multiple clinical applications. Am Fam Physician. 2009, 80: 265-269. PubMed
Denizot F, Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986, 89: 271-277. PubMed
Guan D, Xu Y, Yang M, Wang H, Wang X, Shen Z: N-acetyl cysteine and penicillamine induce apoptosis via the ER stress response-signaling pathway. Mol Carcinog. 2010, 49: 68-74. PubMed
Herzer K, Hofmann T, Teufel A, Schimanski C, Moehler M, Kanzler S, Schulze-Bergkamen H, Galle P: IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009, 69: 855-862. 10.1158/0008-5472.CAN-08-2831. CrossRefPubMed
Lim dY, Jeong Y, Tyner A, Park J: Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol. 2007, 292: G66-G75. CrossRef
Bekisz J, Baron S, Balinsky C, Morrow A, Zoon K: Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel). 2010, 3: 994-1015. CrossRef
Hagiwara S, Kudo M, Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park A, Munakata H: The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon alpha-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol. 2010, 46: 212-221. CrossRefPubMed
Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G: Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 2012, -
Ceballos MP, Parody JP, Alvarez ML, Ingaramo PI, Carnovale CE, Carrillo MC: Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma?. Biochem Pharmacol. 2011, 82: 1682-1691. 10.1016/j.bcp.2011.08.001. CrossRefPubMed
North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, Goessling W: PGE2-regulated wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci U S A. 2010, 107: 17315-17320. 10.1073/pnas.1008209107. PubMedCentralCrossRefPubMed
Jost P, Ruland J: Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007, 109: 2700-2707. PubMed
Chen GQY, Yao J, Jiang Q, Lin X, Chen F, Lin F, Lin M, Lin L, Zhu P: Construction of NF-kappaB-targeting RNAi adenovirus vector and the effect of NF-kappaB pathway on proliferation and apoptosis of vascular endothelial cells. Mol Bio Rep. 2010, 38: 3089-3094. CrossRef
Schubert S, Neeman I, Resnick N: A novel mechanism for the inhibition of NF-kappaB activation in vascular endothelial cells by natural antioxidants. FASEB J. 2002, 16: 1931-1933. PubMed
Havre P, O’Reilly S, McCormick J, Brash D: Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine. Cancer Res. 2002, 62: 1443-1449. PubMed
Ohata K, Ichikawa T, Nakao K, Shigeno M, Nishimura D, Ishikawa H, Hamasaki K, Eguchi K: Interferon alpha inhibits the nuclear factor kappa B activation triggered by X gene product of hepatitis B virus in human hepatoma cells. FEBS Lett. 2003, 553: 304-308. 10.1016/S0014-5793(03)01034-2. CrossRefPubMed
- N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells
Nelson Alexandre Kretzmann
Claudio Augusto Marroni
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II